| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Income tax provision | - | 0 |
| Derivative loss | - | 2,505 |
| Net loss | -22,711 | -12,285 |
| Depreciation and amortization | 123 | 82 |
| Amortization of right of use asset | 259 | 173 |
| Amortization of discount on debt issued | 4,524 | 2,371 |
| Derivative loss | -7,040 | - |
| Provision for excess and obsolete inventory | 643 | 464 |
| Stock-based compensation | 528 | 324 |
| Accounts receivable | 379 | 787 |
| Inventory | -921 | -655 |
| Prepaid expenses and other assets | 105 | -130 |
| Accounts payable | -2,173 | 1,077 |
| Accrued expenses and other liabilities | 318 | 701 |
| Operating lease obligation | -284 | -192 |
| Net cash used in operating activities | -11,296 | -4,782 |
| Net cash used in investing activities | 0 | - |
| Proceeds from loans from related parties | 2,908 | 1,752 |
| Repayments of loans from related parties | 8,214 | 90 |
| Issuance of convertible notes | 2,000 | 2,000 |
| Payments of convertible notes | 25 | - |
| Proceeds from issuance of common stock | 15,209 | 1,485 |
| Proceeds from subscription of common stock | 2,235 | - |
| Repayment of finance lease obligations | 52 | 35 |
| Net cash provided by financing activities | 14,061 | 5,112 |
| Effect of exchange rate changes on cash and cash equivalents | -48 | -16 |
| Net increase (decrease) in cash and cash equivalents | 2,717 | 314 |
| Cash and cash equivalents at beginning of period | 96 | - |
| Cash and cash equivalents at end of period | 2,813 | - |
Picard Medical, Inc. (PMI)
Picard Medical, Inc. (PMI)